Biggest News Aggregation in the World
📰 Phra News

Page 31 - Phra News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Phra. Real-time updates on events, politics, business and more.

Brand Institute, Inc.: MHRA Approves XEVUDY (sotrovimab), GlaxoSmithKline and Vir Biotechnology's Monoclonal Antibody Treatment for Patients with COVID-19

The brand name XEVUDY was developed in partnership with Brand Institute, the global leader in pharmaceutical and healthcare-related name development MIAMI, Dec. 7, 2021 /PRNewswire/ --
United States Scott Piergrossi Jamesl Dettore Drug Safety Institute Brand Institute World Health Organization

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Cosmetic surgery review welcome but overdue: ALA

Following many new, concerning revelations of the negative practices within the cosmetic surgery industry, the Australian Health Practitioner Regulation Agency has announced it would be commissioning an external review. Although a welcome move, a national legal body is concerned that it has come too late.
Daniel Lanzer Naomi Neilson Ngaire Watson Australian Health Practitioner Regulation Agency Australian Lawyers Alliance Australian Health Practitioner Regulation Agency Aphra

14-Year-Old Girl Drives the 1,400-HP Hoonicorn, Challenges a 4,000-HP Corvette

Some 10 years ago, I did my first ever podcast with a local pro drifter that was driving a Nissan S14 at the time. These days, he is still driving, but his main focus shifted towards his 14-year-old daughter. With her father's guidance, she won an International Drifting Challenge, proving that kids are the future of motorsport.
Ken Block Rimac Nevera International Drifting International Drifting Challenge Year Old Girl Drives Hoonicorn Mustang

Britain approves Merck's COVID-19 pill in world first

Britain's Medicines and Healthcare products Regulatory Agency (MHRA) recommended https://www.gov.uk/government/news/first-oral-antiviral-for-covid-19-lagevrio-molnupiravir-approved-by-mhra the drug, molnupiravir, for use in people with mild to moderate COVID-19 and at least one risk factor for developing severe illness, such as obesity, older age diabetes, and heart disease. It will be administered as soon as possible following a positive COVID-19 test and within five days of the onset of s...
United States United Kingdom Maggie Throup Merck Molnupiravir Ridgeback Biotherapeutics June Raine

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science